STOCKHOLM, Sweden, March 26, 2002 (PRIMEZONE) -- Gambro AB (Stockholmsborsen:GAMBaST) (Stockholmsborsen:GAMBbST), a leading international medical technology and healthcare company, reports the following decisions taken at the Annual General Meeting.
Board of Directors
Claes Dahlback, Sandra Austin Crayton, Gosta Gahrton, Wilbur H Gantz, Peter H Grassmann, Juha P Kokko, Soren Mellstig, Hakan Mogren and Bjorn Svedberg were re-elected members of the Board. Sven Nyman had declined re-election. At the statutory Board meeting following the Annual General Meeting, Claes Dahlback was elected Chairman and Hakan Mogren was elected Vice Chairman.
Dividend
The Meeting approved a dividend for 2001 of SEK 1.10 per share, with a record date of March 28, 2002. With this record date, dividends are expected to be paid from VPC (The Swedish Central Securities Depository and Clearing Organisation) on April 4, 2002.
Purchase and Sale of the Company's Own Shares
The proposed authority for the Board to decide on the purchase and sale of the Company's own shares was approved. In short this includes authority for the Board to decide on the acquisition of own shares subject to certain conditions as well as authority to dispose of own shares subject to certain conditions.
Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with about 50,900 patients in more than 670 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, bloodlines and dialysis concentrates. Gambro BCT is the market leader in separation and handling of blood components. The group, with revenues of approximately SEK 27 billion (USD 2.7 billion), has 20,400 employees in some 40 countries.
This information was brought to you by Waymaker http://www.waymaker.net